Ionis Pharmaceuticals, Inc. announced that directors B. Lynne Parshall and Joseph H. Wender will retire from the Board at the end of their current terms at the 2026 Annual Meeting on June 4, 2026, and Peter N. Reikes will rejoin the Board on the same date. These changes were disclosed via press release under Items 5.02 and 7.01.
Key takeaways
B. Lynne Parshall retiring from Board at end of term on June 4, 2026; served over 25 years as director and prior executive roles including COO and CFO.
Joseph H. Wender, Lead Independent Director, retiring from Board at end of term on June 4, 2026; served over 32 years.
Peter N. Reikes appointed to rejoin Board on June 4, 2026; previously served 2018-2021.
Reikes' recent roles: senior strategy advisor at ARPA-H (Dec 2024-Feb 2026) and senior advisor to FDA.
Reikes to receive standard non-employee director compensation per Third Amended Non-Employee Director Compensation Policy.
Press release furnished as Exhibit 99.1 dated March 9, 2026.